551 related articles for article (PubMed ID: 31722152)
1. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
Hatemi G; Mahr A; Ishigatsubo Y; Song YW; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
N Engl J Med; 2019 Nov; 381(20):1918-1928. PubMed ID: 31722152
[TBL] [Abstract][Full Text] [Related]
2. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
Hatemi G; Melikoglu M; Tunc R; Korkmaz C; Turgut Ozturk B; Mat C; Merkel PA; Calamia KT; Liu Z; Pineda L; Stevens RM; Yazici H; Yazici Y
N Engl J Med; 2015 Apr; 372(16):1510-8. PubMed ID: 25875256
[TBL] [Abstract][Full Text] [Related]
3. Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.
Hatemi G; Mahr A; Takeno M; Kim DY; Saadoun D; Direskeneli H; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
Clin Exp Rheumatol; 2021; 39 Suppl 132(5):80-87. PubMed ID: 34622764
[TBL] [Abstract][Full Text] [Related]
4. Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study.
Takeno M; Dobashi H; Tanaka Y; Kono H; Sugii S; Kishimoto M; Cheng S; McCue S; Paris M; Chen M; Ishigatsubo Y
Mod Rheumatol; 2022 Feb; 32(2):413-421. PubMed ID: 34894266
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience.
De Luca G; Cariddi A; Campochiaro C; Vanni D; Boffini N; Tomelleri A; Cavalli G; Dagna L
Rheumatology (Oxford); 2020 Jan; 59(1):171-175. PubMed ID: 31280296
[TBL] [Abstract][Full Text] [Related]
6. Apremilast: A Review in Oral Ulcers of Behçet's Disease.
Deeks ED
Drugs; 2020 Feb; 80(2):181-188. PubMed ID: 31933168
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behçet's syndrome.
Özdede A; Hatemi G
Expert Opin Pharmacother; 2021 Aug; 22(12):1533-1537. PubMed ID: 34218739
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of apremilast for 3 months in Behçet's disease: A prospective observational study.
Hirahara L; Kirino Y; Soejima Y; Takeno M; Takase-Minegishi K; Yoshimi R; Takeuchi M; Mizuki N; Nakajima H
Mod Rheumatol; 2021 Jul; 31(4):856-861. PubMed ID: 32996801
[TBL] [Abstract][Full Text] [Related]
9. Positioning of apremilast in treatment of Behçet's disease.
Takeno M
Mod Rheumatol; 2020 Mar; 30(2):219-224. PubMed ID: 31747804
[TBL] [Abstract][Full Text] [Related]
10. Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.
Hatemi G; Mahr A; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35798511
[TBL] [Abstract][Full Text] [Related]
11. Apremilast to treat oral ulcers in Behçet syndrome.
Yazici H
Drugs Today (Barc); 2020 May; 56(5):303-310. PubMed ID: 32406877
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
[TBL] [Abstract][Full Text] [Related]
14. Interventions for the management of oral ulcers in Behçet's disease.
Taylor J; Glenny AM; Walsh T; Brocklehurst P; Riley P; Gorodkin R; Pemberton MN
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD011018. PubMed ID: 25254615
[TBL] [Abstract][Full Text] [Related]
15. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of apremilast and its impact on serum cytokine levels in patients with Behçet's disease.
Wakiya R; Ushio Y; Ueeda K; Kameda T; Shimada H; Nakashima S; Kato M; Miyagi T; Sugihara K; Mizusaki M; Mino R; Kadowaki N; Dobashi H
Dermatol Ther; 2022 Aug; 35(8):e15616. PubMed ID: 35668044
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
18. Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study.
Vieira M; Buffier S; Vautier M; Le Joncour A; Jamilloux Y; Gerfaud-Valentin M; Bouillet L; Lazaro E; Barete S; Misery L; Gobert D; Goulenok T; Fain O; Sacre K; Sève P; Cacoub P; Comarmond C; Saadoun D
Front Immunol; 2020; 11():626792. PubMed ID: 33613571
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM
Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of apremilast on genital ulcers, skin lesions, and arthritis in patients with Behçet's disease: A systematic review and meta-analysis.
Iizuka Y; Takase-Minegishi K; Hirahara L; Kirino Y; Soejima Y; Namkoong HO; Horita N; Yoshimi R; Takeuchi M; Takeno M; Mizuki N; Nakajima H
Mod Rheumatol; 2022 Oct; 32(6):1153-1162. PubMed ID: 34752620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
